Daglozin M 5/1000mg Tablet

Daglozin M 5/1000mg Tablet is a combination medication composed of two active ingredients: Dapagliflozin & Metformin Hydrochloride (HCI). Dapagliflozin is classified as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, while Metformin HCI is a biguanide antidiabetic drug. This tablet is prescribed for the management of type 2 diabetes mellitus in adults, working through different mechanisms to control blood sugar levels effectively.

Uses:

Daglozin M 5/1000mg Tablet is utilized to improve glycemic control in adults diagnosed with type 2 diabetes mellitus. Dapagliflozin acts by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion in urine and consequent reduction in blood sugar levels. Metformin HCI primarily targets hepatic glucose production, enhances insulin sensitivity, and improves peripheral glucose uptake, collectively contributing to better glycemic control.

Dosage:

The dosage of Daglozin M 5/1000mg Tablet is determined by the healthcare provider based on individual factors such as the patient’s medical history, renal function, and response to treatment. Typically, it is taken orally twice daily with meals to minimize gastrointestinal side effects associated with Metformin HCI. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed.

Side Effects:

Common side effects associated with Daglozin M 5/1000mg Tablet may include urinary tract infections, genital yeast infections, increased urination, thirst, dizziness, nausea, diarrhea, abdominal discomfort, and headache. These side effects are generally mild and transient. However, more severe adverse reactions like hypoglycemia (low blood sugar), ketoacidosis, or allergic reactions may occur in some cases. Patients should promptly report any concerning symptoms to their healthcare provider.

Precautions:

Before initiating Daglozin M 5/1000mg Tablet, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. Since this medication may interact with other drugs, it’s essential to review the patient’s medication regimen to avoid potential interactions. Caution is warranted in patients with impaired renal function or a history of ketoacidosis.

When Not to Use:

Daglozin M 5/1000mg Tablet is contraindicated in patients with a known hypersensitivity to Dapagliflozin, Metformin HCI, or any other components of the medication. It should not be used in individuals with type 1 diabetes mellitus or diabetic ketoacidosis. Additionally, patients with severe renal impairment, end-stage renal disease, or a history of lactic acidosis should avoid this medication.